Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by S100A2 is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. Additionally we are shipping S100A2 Proteins (16) and S100A2 Kits (11) and many more products for this protein.
Showing 10 out of 40 products:
Human Monoclonal S100A2 Primary Antibody for IF, WB - ABIN4948254
Shimada, Miyagawa, Kawashima, Tanaka, Honda, Honda, Tokunaga: An approach based on a genome-wide association study reveals candidate loci for narcolepsy. in Human genetics 2010
Show all 5 references for ABIN4948254
Human Monoclonal S100A2 Primary Antibody for ELISA, WB - ABIN396846
van Dieck, Lum, Teufel, Fersht: S100 proteins interact with the N-terminal domain of MDM2. in FEBS letters 2010
Show all 5 references for ABIN396846
Cow (Bovine) Monoclonal S100A2 Primary Antibody for EIA, IF - ABIN492686
Carolan, Heguy, Harvey, Leopold, Ferris, Crystal: Up-regulation of expression of the ubiquitin carboxyl-terminal hydrolase L1 gene in human airway epithelium of cigarette smokers. in Cancer research 2006
These results indicate that oxidative stress impairs the ability of S100 proteins to bind and activate PP5 (show PPP5C Antibodies), which in turn modulates the ASK1 (show MAP3K5 Antibodies)-mediated signaling cascades involved in apoptosis.
high S100A2 expression and NSCLC
Our results indicate that serum levels of S100A2 and S100A6 (show S100A6 Antibodies) are significantly elevated in early stage non-small cell lung cancer
S100A2 could have a role in poor prognosis in stage II and III colorectal cancer recurrence
The potential of cytoplasmic S100A2 overexpression as a predictor of recurrence risk in oral squamous cell carcinoma patients.
Data show higher expression level of S100A2 in high-invasive cholangiocarcinoma Cell Line suggesting it as potential marker of tumor progression and novel therapeutic target.
Our investigation complements the current understanding of laryngeal cancer progression. Furthermore, this study supports the concept that enhanced expression of S100A2 may be a promising strategy in developing novel cancer therapeutic drugs.
These data demonstrate the importance of S100A2 downstream of the BRCA1/DeltaNp63 signalling axis in modulating transcriptional responses and enforcing growth control mechanisms through destabilisation of mutant p53 (show TP53 Antibodies).
loss of S100A2 expression contributes to Ggastric cancer development and progression.
S100A2 protumorigenic actions and its involvement in TGF-beta (show TGFB1 Antibodies)-mediated cancer cell invasion and epithelial-mesenchymal transition.
S100A2 and S100A6 (show S100A6 Antibodies) interact with another TPR (show GRID2 Antibodies) protein Tom70 (show TOMM70A Antibodies) and regulate the Tom70 (show TOMM70A Antibodies)-ligand interaction in vitro
Survival after UVA irradiation was greater in human keratinocytes compared to mouse skin with no S100A2 expression, showing a protective role for S100A2. A S100A2-dependent difference was observed in the induction of Cxcl13 (show CXCL13 Antibodies) transcripts in transgenic mice.
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may have a tumor suppressor function. Chromosomal rearrangements and altered expression of this gene have been implicated in breast cancer.
S100 calcium binding protein A2
, S100 calcium-binding protein A2
, protein S100-A2
, predicted gene, EG628324